Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center.

CONTEXT Laboratories must validate all assays before they can be used to test patient specimens, but currently there are no evidence-based guidelines regarding validation of immunohistochemical assays. OBJECTIVE To develop recommendations for initial analytic validation and revalidation of immunohistochemical assays. DESIGN The College of American Pathologists Pathology and Laboratory Quality Center convened a panel of pathologists and histotechnologists with expertise in immunohistochemistry to develop validation recommendations. A systematic evidence review was conducted to address key questions. Electronic searches identified 1463 publications, of which 126 met inclusion criteria and were extracted. Individual publications were graded for quality, and the key question findings for strength of evidence. Recommendations were derived from strength of evidence, open comment feedback, and expert panel consensus. RESULTS Fourteen guideline statements were established to help pathology laboratories comply with validation and revalidation requirements for immunohistochemical assays. CONCLUSIONS Laboratories must document successful analytic validation of all immunohistochemical tests before applying to patient specimens. The parameters for cases included in validation sets, including number, expression levels, fixative and processing methods, should take into account intended use and should be sufficient to ensure that the test accurately measures the analyte of interest in specimens tested in that laboratory. Recommendations are also provided for confirming assay performance when there are changes in test methods, reagents, or equipment.

[1]  T. Grogan,et al.  A New Rabbit Monoclonal Antibody (4B5) for the Immunohistochemical (IHC) Determination of the HER2 Status in Breast Cancer: Comparison With CB11, Fluorescence In Situ Hybridization (FISH), and Interlaboratory Reproducibility , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[2]  Rhona J. Souers,et al.  Laboratory compliance with the American Society of Clinical Oncology/college of American Pathologists guidelines for human epidermal growth factor receptor 2 testing: a College of American Pathologists survey of 757 laboratories. , 2010, Archives of pathology & laboratory medicine.

[3]  Eileen Erinoff,et al.  Addressing Challenges in Genetic Test Evaluation: Evaluation Frameworks and Assessment of Analytic Validity , 2011 .

[4]  S. Temin,et al.  Systematic Review on Hormone Receptor Testing in Breast Cancer , 2012, Applied immunohistochemistry & molecular morphology : AIMM.

[5]  S. Boccia,et al.  Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease , 2005, Preventing Chronic Disease.

[6]  G. Fountzilas,et al.  Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays. , 2013, Anticancer research.

[7]  J. Bart,et al.  Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer , 2009, Modern Pathology.

[8]  C. di Loreto,et al.  Hormone receptor and human epidermal growth factor receptor 2 status evaluation on ThinPrep specimens from breast carcinoma , 2012, Cancer cytopathology.

[9]  Xin He,et al.  Validation of Methods for Oropharyngeal Cancer HPV Status Determination in US Cooperative Group Trials , 2012, The American journal of surgical pathology.

[10]  C. Goodman,et al.  Food and Drug Administration Center for Devices and Radiological Health , 1988 .

[11]  E. Hsi.  A practical approach for evaluating new antibodies in the clinical immunohistochemistry laboratory. , 2001, Archives of pathology & laboratory medicine.

[12]  Clive R Taylor,et al.  Recommendations for Improved Standardization of Immunohistochemistry , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[13]  Hugo M. Lourenço,et al.  HER2/Neu Detection by Immunohistochemistry: Optimization of In-house Protocols , 2009, Applied immunohistochemistry & molecular morphology : AIMM.

[14]  B. Rasmussen,et al.  Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays , 2006, Journal of Clinical Pathology.

[15]  Dylan Reilly,et al.  Standardization of HER2 immunohistochemistry in breast cancer by automated quantitative analysis. , 2009, Archives of pathology & laboratory medicine.

[16]  M. J. van de Vijver,et al.  Assessment of a HER2 scoring system for gastric cancer: results from a validation study , 2008, Histopathology.

[17]  M. Ehinger,et al.  Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B‐cell lymphoma , 2007, European journal of haematology.

[18]  M. Prasad,et al.  Comparative evaluation of high-throughput small-core (0.6-mm) and large-core (2-mm) thyroid tissue microarray: is larger better? , 2012, Archives of pathology & laboratory medicine.

[19]  G. Lauer,et al.  Immunohistochemical comparison of differentiation markers on paraffin and plastic embedded human bone samples. , 2009, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[20]  M. Espié,et al.  Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches , 2011, British Journal of Cancer.

[21]  D. Faratian,et al.  Tissue microarray technology in the routine assessment of HER‐2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization , 2008, Histopathology.

[22]  Y. Rustum,et al.  Double Immunohistochemical Staining Method for HIF-1α and its Regulators PHD2 and PHD3 in Formalin-fixed Paraffin-embedded Tissues , 2010, Applied immunohistochemistry & molecular morphology : AIMM.

[23]  Mark Leys,et al.  Health care policy: qualitative evidence and health technology assessment. , 2003, Health policy.

[24]  Maria J Grant,et al.  A typology of reviews: an analysis of 14 review types and associated methodologies. , 2009, Health information and libraries journal.

[25]  Anthony Rhodes,et al.  Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. , 2002, American journal of clinical pathology.

[26]  M. Vyberg,et al.  Demonstration of CDX2 is Highly Antibody Dependant , 2012, Applied immunohistochemistry & molecular morphology : AIMM.

[27]  A. Fassina,et al.  Morphological quality and nucleic acid preservation in cytopathology , 2008, Journal of Clinical Pathology.

[28]  G. Birdsong,et al.  Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas , 2009, Cancer.

[29]  A. Rajwanshi,et al.  Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma , 2012, Cytopathology : official journal of the British Society for Clinical Cytology.

[30]  P. Drev,et al.  Tissue Microarrays for Routine Diagnostic Assessment of HER2 Status in Breast Carcinoma , 2008, Applied immunohistochemistry & molecular morphology : AIMM.

[31]  F. Schmitt,et al.  HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas , 2006, Journal of Clinical Pathology.

[32]  M. Bui,et al.  The CD117 immunohistochemistry tissue microarray survey for quality assurance and interlaboratory comparison: a College of American Pathologists Cell Markers Committee Study. , 2006, Archives of pathology & laboratory medicine.

[33]  P. Adegboyega,et al.  Effect of Decalcification on the Immunohistochemical Expression of ABH Blood Group Isoantigens , 2003, Applied immunohistochemistry & molecular morphology : AIMM.

[34]  H. Wiker,et al.  Rapid and Specific Diagnosis of Tuberculous Pleuritis With Immunohistochemistry by Detecting Mycobacterium Tuberculosis Complex Specific Antigen MPT64 in Patients From a HIV Endemic Area , 2008, Applied immunohistochemistry & molecular morphology : AIMM.

[35]  S. Teutsch,et al.  The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group , 2009, Genetics in Medicine.

[36]  M. Dowsett,et al.  Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box , 2011, BMC medicine.

[37]  C. Forster,et al.  Concordance Between Tissue Microarray and Whole-section Estrogen Receptor Expression and Intratumoral Heterogeneity , 2012, Applied immunohistochemistry & molecular morphology : AIMM.

[38]  Glenn A. Bowen.  Document Analysis as a Qualitative Research Method , 2009 .

[39]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[40]  G. Tate,et al.  Comparison of immunocytochemical sensitivity between formalin-fixed and alcohol-fixed specimens reveals the diagnostic value of alcohol-fixed cytocentrifuged preparations in malignant effusion cytology. , 2011, American journal of clinical pathology.

[41]  D. Arber.  Effect of Prolonged Formalin Fixation on the Immunohistochemical Reactivity of Breast Markers , 2002, Applied immunohistochemistry & molecular morphology : AIMM.

[42]  T. Thomson,et al.  Tissue microarray for routine analysis of breast biomarkers in the clinical laboratory. , 2009, American journal of clinical pathology.

[43]  D. Mayr,et al.  Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest™ (Dako) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH) , 2009, Virchows Archiv.

[44]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[45]  H. Körner,et al.  Androgen Receptor Determination in Breast Cancer: A Comparison of the Dextran-coated Charcoal Method and Quantitative Immunohistochemical Analysis , 2008, Applied immunohistochemistry & molecular morphology : AIMM.

[46]  A. Chan,et al.  The contribution of bifunctional SkipDewax pretreatment solution, rabbit monoclonal antibodies, and polymer detection systems in immunohistochemistry. , 2007, Archives of pathology & laboratory medicine.

[47]  G. Stenman,et al.  HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry. , 2010, Pathology, research and practice.

[48]  H. Cramer,et al.  ER, PR, and Her2 immunocytochemistry on cell‐transferred cytologic smears of primary and metastatic breast carcinomas: A Comparison Study With Formalin‐Fixed Cell Blocks and Surgical Biopsies , 2013, Diagnostic cytopathology.

[49]  Rhona J. Souers,et al.  Immunohistochemistry validation procedures and practices: a College of American Pathologists survey of 727 laboratories. , 2013, Archives of pathology & laboratory medicine.

[50]  B. Gilks,et al.  Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests. , 2010, American journal of clinical pathology.

[51]  M. Gulley,et al.  Recommended principles and practices for validating clinical molecular pathology tests. , 2009, Archives of pathology & laboratory medicine.

[52]  J. Brock,et al.  A comparison of equivocal immunohistochemical results with anti-HER2/neu antibodies A0485 and SP3 with corresponding FISH results in routine clinical practice. , 2011, American journal of clinical pathology.

[53]  Comparison of tissue microarray and full section in immunohistochemistry of gastrointestinal stromal tumors , 2009, Pathology international.

[54]  Jianfeng Xu,et al.  PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients , 2011, Clinical Cancer Research.

[55]  S. Tripp,et al.  A comparison of immunohistochemical stain quality in conventional and rapid microwave processed tissues. , 2006, American journal of clinical pathology.

[56]  E. Provenzano,et al.  An Immunohistochemical and Fluorescence In Situ Hybridization-based Comparison Between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH Using Both Commercially Validated and Modified ASCO/CAP and United Kingdom HER2 IHC Scoring Guidelines , 2010, Applied immunohistochemistry & molecular morphology : AIMM.

[57]  B. Rerkamnuaychoke,et al.  Human epidermal growth-factor receptor 2 overexpression in gastric carcinoma in Thai patients. , 2012, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[58]  Donald A Berry,et al.  NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[59]  J. Kim,et al.  Stimulation of large-conductance Ca2+-activated K+ channels by the Na+/Ca2+ exchanger inhibitor dichlorobenzamil in cultured human umbilical vein endothelial cells and mouse aortic smooth muscle cells. , 2009, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[60]  D. Allred,et al.  Development of Standard Estrogen and Progesterone Receptor Immunohistochemical Assays for Selection of Patients for Antihormonal Therapy , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[61]  E. Murphy,et al.  Qualitative research methods in health technology assessment: a review of the literature. , 1998, Health technology assessment.

[62]  A. Tzankov,et al.  Modern techniques for the diagnostic evaluation of the trephine bone marrow biopsy: methodological aspects and applications. , 2008, Progress in histochemistry and cytochemistry.

[63]  N. Sneige,et al.  Optimal fixation conditions for immunocytochemical analysis of estrogen receptor in cytologic specimens of breast carcinoma , 2003, Cancer.

[64]  J. Lanchbury,et al.  A Robust Immunohistochemical Assay for Detecting PTEN Expression in Human Tumors , 2011, Applied immunohistochemistry & molecular morphology : AIMM.

[65]  V. Livolsi,et al.  TTF-1 Expression in Ovarian and Uterine Epithelial Neoplasia and its Potential Significance, an Immunohistochemical Assessment With Multiple Monoclonal Antibodies and Different Secondary Detection Systems , 2009, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[66]  K. Jirström,et al.  Quality aspects of the tissue microarray technique in a population‐based cohort with ductal carcinoma in situ of the breast , 2008, Histopathology.

[67]  A. Mulligan,et al.  The Effect of Prolonged Fixation on the Immunohistochemical Evaluation of Estrogen Receptor, Progesterone Receptor, and HER2 Expression in Invasive Breast Cancer: A Prospective Study , 2011, The American journal of surgical pathology.

[68]  M. Vyberg,et al.  Thyroid Transcription Factor-1 in Primary CNS Tumors , 2011, Applied immunohistochemistry & molecular morphology : AIMM.

[69]  T. Molina,et al.  Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin , 2005, Modern Pathology.

[70]  J. E. Boers,et al.  HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH) , 2011, Histopathology.

[71]  Manfred Dietel,et al.  HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing , 2010, Virchows Archiv.

[72]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[73]  O. Nielsen,et al.  Optimization of Antibodies for Detection of the Mismatch Repair Proteins MLH1, MSH2, MSH6, and PMS2 Using a Biotin-Free Visualization System , 2006, Applied immunohistochemistry & molecular morphology : AIMM.

[74]  H. Kataoka,et al.  Optimization of tissue processing for immunohistochemistry for the detection of human glypican-3. , 2010, Acta histochemica.

[75]  Helen M. Moore,et al.  Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. , 2011, Archives of pathology & laboratory medicine.

[76]  G. Bussolati,et al.  Technical pitfalls potentially affecting diagnoses in immunohistochemistry , 2008, Journal of Clinical Pathology.

[77]  Johannes B Reitsma,et al.  Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies , 2006, BMC medical research methodology.

[78]  M. Hammond,et al.  Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. , 2010, Archives of pathology & laboratory medicine.

[79]  P. V. van Diest,et al.  Validation of a Fully Automated HER2 Staining Kit in Breast Cancer , 2010, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[80]  Christopher Otis,et al.  Quality assurance for design control and implementation of immunohistochemistry assays; Approved guidelinesecond edition , 2011 .

[81]  Ping Tang,et al.  Tissue microarray-based immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast , 2011, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[82]  J. D. van der Walt,et al.  Call for a European programme in external quality assurance for bone marrow immunohistochemistry; report of a European Bone Marrow Working Group pilot study , 2009, Journal of Clinical Pathology.

[83]  M. Dowsett,et al.  Standardization of HER2 testing: results of an international proficiency-testing ring study , 2007, Modern Pathology.

[84]  G. Mills,et al.  Clinical Assessment of PTEN Loss in Endometrial Carcinoma: Immunohistochemistry Out-Performs Gene Sequencing , 2011, Modern Pathology.

[85]  G. Sauter,et al.  HER-2/neu analysis in breast cancer bone metastases , 2009, Journal of Clinical Pathology.

[86]  D. Murphy,et al.  Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey. , 2009, Archives of pathology & laboratory medicine.

[87]  M. Peterson,et al.  Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma , 2011, Diagnostic cytopathology.

[88]  F. O'Malley,et al.  Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer , 2007, Current oncology.

[89]  K. Aogi,et al.  Usefulness of liquid-based cytology in hormone receptor analysis of breast cancer specimens , 2011, Virchows Archiv.

[90]  K. Allison,et al.  Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases. , 2010, American journal of clinical pathology.

[91]  J. van der Velden,et al.  Validation of tissue microarray technology in endometrioid cancer of the endometrium , 2006, Journal of Clinical Pathology.

[92]  L. Rogers,et al.  Fixation time does not affect expression of HER2/neu: a pilot study. , 2010, American journal of clinical pathology.

[93]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[94]  M. J. van de Vijver,et al.  Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer , 2009, Clinical Cancer Research.